Last reviewed · How we verify

Sham injection + laser

Jaeb Center for Health Research · Phase 3 active Small molecule Under review

Sham injection + laser is a Small molecule drug developed by Jaeb Center for Health Research. It is currently in Phase 3 development for Treatment of psoriasis. Also known as: placebo.

This drug combines a sham injection with laser therapy, which is a non-pharmacological treatment approach.

Sham injection is a control intervention used in clinical trials for conditions such as Weiss Ring, Floaters, and Diabetic Retinopathy, often in conjunction with laser treatment. The exact mechanism of Sham injection is unknown, as it is classified as a compound solution of sodium chloride, similar to Ringer's injection, but its specific formulation and effects are not well-documented.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameSham injection + laser
Also known asplacebo
SponsorJaeb Center for Health Research
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

The sham injection serves as a placebo control, while the laser therapy is used to stimulate tissue repair or reduce inflammation. The exact mechanism of action is not well understood, but it is thought to involve the activation of various cellular pathways that promote healing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sham injection + laser

What is Sham injection + laser?

Sham injection + laser is a Small molecule drug developed by Jaeb Center for Health Research, indicated for Treatment of psoriasis.

How does Sham injection + laser work?

This drug combines a sham injection with laser therapy, which is a non-pharmacological treatment approach.

What is Sham injection + laser used for?

Sham injection + laser is indicated for Treatment of psoriasis.

Who makes Sham injection + laser?

Sham injection + laser is developed by Jaeb Center for Health Research (see full Jaeb Center for Health Research pipeline at /company/jaeb-center-for-health-research).

Is Sham injection + laser also known as anything else?

Sham injection + laser is also known as placebo.

What development phase is Sham injection + laser in?

Sham injection + laser is in Phase 3.

What are the side effects of Sham injection + laser?

Common side effects of Sham injection + laser include Skin irritation.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing